Skip to nav Skip to content

Clinical Trial Search

307 Clinical Trials Found

Clinical Trial 21035

A Pilot Study of Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)
Disease Site: Lymphoid Leukemia
PI: Dong, Ning

Clinical Trial 20752

A Phase 1 Study of Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated Acute Myeloid Leukemia
Disease Site: Leukemia, other, Myeloid and Monocytic Leukemia
PI: Chan, Onyee

Clinical Trial 21383

A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)
Disease Site: Other Digestive Organ, Other Endocrine System
PI: Strosberg, Jonathan

Clinical Trial 22380

A Phase II Multicenter, Open Label, Non-Randomized Study of Neoadjuvant and Adjuvant Treatment with IPH5201 and Durvalumab in Patients with Resectable, Early-Stage (II To IIIA) Non-Small Cell Lung CancEr (MATISSE)
Disease Site: Lung
PI: Chiappori, Alberto

Clinical Trial 22595

Disease Site: Multiple Myeloma
PI: Paba Prada, Claudia

Clinical Trial 23059

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome
Disease Site: Myeloid and Monocytic Leukemia
PI: Sallman, David

Clinical Trial 23063

An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer
Disease Site: Breast
PI: Han, Heather

Clinical Trial 20386

Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC
Disease Site: Lung
PI: Gray, Jhanelle

Clinical Trial 20339

Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma
Disease Site: Bones and Joints, Rhabdomyosarcoma
PI: Metts, Jonathan

Clinical Trial 20110

GBM Agile: Global Adaptive Trial Master Protocol
Disease Site: Brain and Nervous System
PI: Grogan, Patrick

Clinical Trial 20305

Phase 1/1b Trial of Donor gamma delta T-cell Infusion for Treatment of Patients with Acute Myeloid Leukemia at High Risk of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
Disease Site: Leukemia, other, Myeloid and Monocytic Leukemia
PI: Bejanyan, Nelli

Clinical Trial 20871

A Phase 3, Open-label, Randomized, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT)
Disease Site: Unknown Sites
PI: Nishihori, Taiga